Sean Wuxiong Cao - 03 Sep 2026 Form 4 Insider Report for NovaBridge Biosciences (NBP)

Reporting relationship: Chief Bus. Development Officer
Issuer ticker: NBP
Reported as of: 03 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Sep 2026, 17:51:01 UTC
Prior SEC filing: 24 Jun 2026
Next SEC filing: 11 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Kyler Lei as attorney-in-fact

Key filing fact

Sean Wuxiong Cao filed Form 4 for NovaBridge Biosciences (NBP) on 08 Sep 2026.

Key facts

This page summarizes Sean Wuxiong Cao's Form 4 filing for NovaBridge Biosciences (NBP).
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 08 Sep 2026, 17:51.

Change

Previous filing in this sequence was filed on 24 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002109966 Primary reporting owner

Cao Sean Wuxiong

Relationship: Chief Bus. Development Officer
Address: C/O NOVABRIDGE BIOSCIENCES, 2440 RESEARCH BOULEVARD, SUITE 400, ROCKVILLE
Signature: /s/ Kyler Lei as attorney-in-fact
Signature date: 08 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NBP transaction

Ordinary Shares

Options Exercise

Transaction value
Shares: +235,136
Change %: +670%
Price
Shares after: 270,209
Date: 03 Sep 2026
Ownership: Direct
Footnotes: F1, F2, F3

NBP transaction

Ordinary Shares

Options Exercise

Transaction value
Shares: +104,236
Change %: +39%
Price
Shares after: 374,445
Date: 03 Sep 2026
Ownership: Direct
Footnotes: F1, F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NBP transaction Derivative

Restricted Share Units

Options Exercise

Transaction value
Shares: -102,233
Change %: -25%
Price: $0.000000^*
Shares after: 306,700
Date: 03 Sep 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 102,233
Exercise price
Footnotes: F1, F3, F5

NBP transaction Derivative

Restricted Share Units

Options Exercise

Transaction value
Shares: -45,320
Change %: -25%
Price: $0.000000^*
Shares after: 135,960
Date: 03 Sep 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 45,320
Exercise price
Footnotes: F1, F3, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

Footnote F2

Reported securities are represented by 102,233 ADSs

Footnote F3

Each restricted stock unit ("RSU") represents a contingent right to receive one ADS.

Footnote F4

Reported securities are represented by 45,320 ADSs.

Footnote F5

On September 3, 2025, the Reporting Person was granted 408,933 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the third day of each third month.

Footnote F6

On June 22, 2026, the Reporting Person was granted 181,280 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on September 3, 2026 and the balance vesting ratably over the subsequent 12 quarters on the third day of each third month.